Production and use of human nm23 protein and antibodies...

Details Production and use of human nm23 protein and antibodies... Production and use of human nm23 protein and antibodies...

1991-12-11

2002-07-23

Ulm, John (Department: 1646)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S069100, C435S252300, C435S320100

Reexamination Certificate

active

06423836

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention relates to human nm
23
protein, DNA encoding human tim
23
proteins (or fragments or analogues of such DNA), antibodies which recognize human nm
23
protein, and processes and products for producing and using such materials.
Steeg et al.,
Journal of the National Cancer Institute
80:200-204, 1988 discloses a murine nm-
23
gene, and corresponding protein which is associated with murine tumor metastatic potential.
SUMMARY OF THE INVENTION
Applicant has provided a human gene(s) encoding for a human nm
23
protein(s), as well as the protein(s) and antibodies which can be used as an aid in predicting the aggressiveness of human tumors.
More specifically, the present invention relates to genetic testing for cancer susceptibility, diagnosis and prognosis. The present invention makes use of the marker of the nm
23
genes, for which the human nm
23
-H
1
and pnm
23
-H
2
S and murine 23 and pnm
23
-
1
recombinant cDNA clones have been described (3, 21-22). The genetic marker itself can be a whole gene, a fragment thereof, a genomic or cDNA clone, an adjacent region, or a regulatory region thereof. The purpose of this invention is to provide novel genetic methods for the detection of (a) susceptibility to cancer and (b) cancer tumorigenic and metastatic potential.
These methods are based on (a) structural and sequential evaluation of nm
23
DNA and; (b) evaluation of novel nm
23
expression patterns, either at the RNA, mRNA and/or protein levels. Such information is critical to the physician's selection of diagnostic and therapeutic regimens for the patient, both prior to the development of cancer and during cancer detection and treatment.
Therefore, in accordance with one aspect of the present invention, there is provided DNA, or a fragment, analogue or derivative of such DNA, which encodes a human nm
23
protein.
In accordance with another aspect of the present invention, there is provided a cloning or expression vehicle which includes DNA, or a fragment, analogue or derivative of such DNA, which encodes a human nm
23
protein.
In accordance with a further aspect of the present invention, there is provided a host; in particular cells, genetically engineered to include DNA, or a fragment or analogue or derivative of such DNA, which encodes a human nm
23
protein or a fragment or analogue or derivative of such DNA; i.e., such cells are modified to include human nm
23
DNA.
In accordance with yet another aspect of the present invention, there is provided a human nm
23
protein.
In accordance with yet a further aspect of the present invention, there is provided antibodies which recognize human nm
23
protein.
In accordance with still a further aspect of the present invention, there is provided procedures for using the aforementioned DNA and antibodies for predicting the metastatic potential of tumors.
The term “human nm
23
gene or DNA” as used herein means a gene or DNA which encodes a human nm
23
protein, or an analogue or derivative or fragment of such DNA or gene which encompasses or includes a DNA sequence unique to DNA which encodes a human nm
23
protein. Thus, the term human nm
23
gene encompasses the genes or DNAs of
FIGS. 6A-6B
or fragments or derivatives or analogues of such genes.
“Human nm
23
protein” means nm
23
protein found in humans, or a fragment, analogue or derivative thereof which encompasses or includes an amino acid sequence which is unique to human nm
23
protein and which preferably elicits an antibody which is recognized by human nm
23
protein. The term human nm
23
protein encompasses the proteins encoded by the genes of
FIGS. 6A-6B
.
The term “antibody” as used herein encompasses polyclonal and monoclonal antibodies.
The term “nm
23
antibody” means an antibody which is elicited in response to human nm
23
protein or which recognizes human nm
23
protein. An antibody which recognizes human nm
23
protein may or may not be elicited in response to human nm
23
protein.


REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 5049662 (1991-09-01), Steeg et al.
Barnes et alAm J. of Pathology139(2):245-250 (1991).*
Bevilacqua et al.Cancer Research49:5185-5190 (Sep. 15, 1990).*
Biggs et al.Cell63:933-40 (1990).*
Gilles et alJ. of Biol Chem266(14):8784-8789 (1991).*
Rosengard et al.Nature342:177-180 (Nov. 9, 1989).*
Stahl et al.Cancer Research51:445-449 (1991).*
Steeg et alJ of the Nat'l Cancer Inst.80(3):200-204 (1988).

Affiliated with

Also associated with

Rating

Production and use of human nm23 protein and antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Production and use of human nm23 protein and antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production and use of human nm23 protein and antibodies... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2910907